- There are reports of issues with accessing the company's new website, flagged by Google as untrusted.
- A list of major shareholders was shared, highlighting no increase in stakes by any, with J. R. Kight holding the largest share.
- Vulpes Investment Management's strategy on investing in underpriced UK biotech companies for long-term gains was discussed.
- Concerns were raised about the amount of shares in general free float versus those considered as long-term safe holdings.
- Speculations were made regarding the delay in the company's name change announced on 4 April.
- Doubts were expressed about the likelihood of directors purchasing more shares, given the low investment levels and the company's current financial standing.
- A large transaction of shares was noted, questioning whether it was a buy or sell.
- AXA was mentioned as the last entity in a stock transfer form, raising questions about the need for a TR1 notification.
- A discussion on the company’s share structure revealed significant holdings by entities like Octopus Investments, SPARK Impact, and others, noting recent price paid at 1p.
- Frustrations were voiced over the recent financial raise considered inadequate and indicative of management issues.
- A shareholder's conversation with the company's head was hinted to cover many concerns, promising to share more detailed notes later.